Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryuzo Ueda

Showing results (21-30 of 333) with videos related to

Pageof 34
Sort By:
European Journal of Gastroenterology & Hepatology|December 5, 2009
A case of compensated liver cirrhosis with hepatitis C virus of genotype 1b and high viral load in whom sustained virological response was achieved by 2-year administration of very low-dose recombinant interferon alpha-2bHideaki Kato, Makoto Nakamura, Atsushi Nakamura, et al.
Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics|August 22, 2002
[Clinical significance of soluble interleukin-2 receptor as a putative systemic nutritional index in the elderly]Motoo Kikuchi, Toshiaki Inagaki, Nagao Shinagawa, et al.
Japanese Journal of Cancer Research : Gann|May 3, 2002
Lack of Ku80 alteration in multiple myelomaMiyuki Kato, Shinsuke Iida, Hirokazu Komatsu, et al.
Hepatology (Baltimore, Md.)|December 19, 2013
Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapyShigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Clinical significance of hepatitis B virus (HBV)-DNA monitoring to detect HBV reactivation after systemic chemotherapyShigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
International Journal of Hematology|June 23, 2009
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphomaShigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
Journal of Gastroenterology|October 7, 2010
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapyShigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?Shigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
Current Alzheimer Research|June 25, 2005
Cognitive event-related potentials: useful clinical information in Alzheimer's diseaseEiichi Katada, Koichi Sato, Kosei Ojika, et al.
Japanese Journal of Clinical Oncology|January 29, 2016
Current status of immunotherapySusumu Suzuki, Takashi Ishida, Kazuhiro Yoshikawa, et al.
Pageof 34

Showing results (21-30 of 333) with videos related to

Sort By:
Pageof 34
European Journal of Gastroenterology & Hepatology|December 5, 2009
A case of compensated liver cirrhosis with hepatitis C virus of genotype 1b and high viral load in whom sustained virological response was achieved by 2-year administration of very low-dose recombinant interferon alpha-2bHideaki Kato, Makoto Nakamura, Atsushi Nakamura, et al.
Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics|August 22, 2002
[Clinical significance of soluble interleukin-2 receptor as a putative systemic nutritional index in the elderly]Motoo Kikuchi, Toshiaki Inagaki, Nagao Shinagawa, et al.
Japanese Journal of Cancer Research : Gann|May 3, 2002
Lack of Ku80 alteration in multiple myelomaMiyuki Kato, Shinsuke Iida, Hirokazu Komatsu, et al.
Hepatology (Baltimore, Md.)|December 19, 2013
Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapyShigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Clinical significance of hepatitis B virus (HBV)-DNA monitoring to detect HBV reactivation after systemic chemotherapyShigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
International Journal of Hematology|June 23, 2009
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphomaShigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
Journal of Gastroenterology|October 7, 2010
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapyShigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?Shigeru Kusumoto, Yasuhito Tanaka, Masashi Mizokami, et al.
Current Alzheimer Research|June 25, 2005
Cognitive event-related potentials: useful clinical information in Alzheimer's diseaseEiichi Katada, Koichi Sato, Kosei Ojika, et al.
Japanese Journal of Clinical Oncology|January 29, 2016
Current status of immunotherapySusumu Suzuki, Takashi Ishida, Kazuhiro Yoshikawa, et al.
Pageof 34